Clinical Trials Directory

Trials / Unknown

UnknownNCT04268108

L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy

Clinical Study of Liquid Tumor Infiltrating Lymphocytes in Patients With Advanced Malignancies Resistance to Anti-PD-1 Therapy

Status
Unknown
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Henan Cancer Hospital · Other Government
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy

Conditions

Interventions

TypeNameDescription
BIOLOGICALliquid tumor infiltrating lymphocytesIsolatation and amplification PD-1+ cells from peripheral blood lymphocytes under GMP conditions for clinical use.

Timeline

Start date
2020-04-02
Primary completion
2022-02-19
Completion
2022-06-19
First posted
2020-02-13
Last updated
2020-06-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04268108. Inclusion in this directory is not an endorsement.

L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy (NCT04268108) · Clinical Trials Directory